Drug Profile
Research programme: antibacterials - Achillion/FOB Synthesis
Alternative Names: FSI-1297; FSI-1671; FSI-1686Latest Information Update: 05 Feb 2020
Price :
$50
*
At a glance
- Originator FOB Synthesis
- Developer Achillion Pharmaceuticals; FOB Synthesis
- Class Carbapenems
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Jan 2020 Achillion Pharmaceuticals has been acquired by Alexion Pharmaceuticals
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Parenteral)
- 25 Jun 2013 Preclinical development is ongoing in USA